The role of partnership in building value
Big Pharma is facing a ‘patent cliff’, and new drugs are subjected to increased scrutiny and rising threshold of innovation from regulatory agencies and healthcare payers. Rising research and development costs are causing downsizing. Meanwhile small biotech start-ups and academic spin-offs are on the increase but face a lack of finance and facilities. More creative partnering arrangements and more open innovation are needed to enable both to thrive.